Enhanced STOPP/START Criteria: A Tool for Managing Polypharmacy in Older Population
Yu. V. Kotovskaya,
O. N. Tkacheva,
N. K. Runikhina,
M. S. Cherniaeva,
I. P. Malaya,
O. M. Maslennikova,
L. A. Egorova,
A. A. Dotsenko https://doi.org/10.37586/2686-8636-4-2023-273-288
Abstract
Polypharmacy in geriatric patients is associated with an increased risk of adverse outcomes. Therefore, several instruments for prescription analysis and optimization can be used to enhance the safety and efficacy of pharmacotherapy in old age population. STOPP/START criteria is one of the most popular screening tools in the Russian Federation and abroad that list potentially inappropriate drugs for use in older patients (STOPP criteria) and potentially prescribed for certain clinical cases (START criteria). Two previous versions of the STOPP/START criteria were published in 2008 and 2015. Released in 2023, the newest (third version) demonstrates the evolution of evidence-based pharmacotherapy for older and oldestold patients, featuring 133 STOPP and 57 START criteria. Expanding the base of STOPP/START criteria should support optimization of prescriptions and reducing ADRs risk in older patients. This article introduces translation of STOPP/START criteria, version 3.
About the Authors
Yu. V. Kotovskaya
Pirogov Russian National Research Medical University, Russian Gerontological Research and Clinical Center
Kotovskaya Yulia V., MD, PhD, professor, Deputy Director
O. N. Tkacheva
Pirogov Russian National Research Medical University, Russian Gerontological Research and Clinical Center
Tkacheva Olga N., MD, PhD, professor, corresponding member of the Russian Academy of Sciences, Director
N. K. Runikhina
Pirogov Russian National Research Medical University, Russian Gerontological Research and Clinical Center
Russian Federation
Russian Federation
Runikhina Nadezhda K., MD, PhD, professor, Deputy Director
M. S. Cherniaeva
Central State Medical Academy of the Presidential Administration of the Russian Federation; State Budgetary Institution of Health “Hospital for War Veterans No. 2” of the Department of Health of Moscow
Cherniaeva Marina S., MD, PhD, Associate professor of the Department of Internal Medicine and Preventive Medicine, Head of the Geriatric
Department; geriatrician, Chief specialist geriatrician of the Department of Health of the city of Moscow in the South-Eastern Administrative
District of Moscow
I. P. Malaya
Pirogov Russian National Research Medical University, Russian Gerontological Research and
Clinical Center
Malaya Irina P., MD, PhD, Head of Clinical Pharmacology and Pharmacotherapy Laboratory
O. M. Maslennikova
Central State Medical Academy of the Presidential Administration of the Russian Federation
Maslennikova Olga M., MD, PhD, professor of the Department of Internal Medicine and Preventive Medicine
L. A. Egorova
Central State Medical Academy of the Presidential Administration of the Russian Federation
Yegorova Larisa A., MD, PhD, professor of the Department of Internal Medicine and Preventive Medicine
A. A. Dotsenko
Central State Medical Academy of the Presidential Administration of the Russian Federation
Dotsenko Alexey A., resident doctor of the Department of Internal Medicine and Preventive Medicine
References
1. Gutiérrez-Valencia M., Izquierdo M., Cesari M., et al. The relationship between frailty and polypharmacy in older people: Asystematic review. Br J Clin Pharmacol. 2018;84(7):1432-1444. doi: 10.1111/bcp.13590.
2. Maher R.L., Hanlon J., Hajjar E.R. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65. doi: https://doi.org/10.1517/14740338.2013.827660.
3. Hein C., Forgues A., Piau A., et al. Impact of polypharmacy on occurrence of delirium in elderly emergency patients. J Am Med Dir Assoc. 2014;15(11):850.e11-15. doi: https://doi.org/10.1016/j.jamda.2014.08.012.
4. Machado-Duque M.E, Castaño-Montoya J.P., Medina-Morales D.A, et al. Drugs with Anticholinergic Potential and Risk of Falls with Hip Fracture in the Elderly Patients: A Case-Control Study. J Geriatr Psychiatry Neurol. 2018;31(2):63-69. doi: https://doi.org/10.1016/j.rcp.2020.11.004
5. Hanlon J.T., Handler S.M., Maher R.L., Schmader K.E. Geriatric Pharmacotherapy and Polypharmacy. In: Fillit H.M., Rockwood K., Young J.B. Brocklehurst's Textbook of Geriatric Medicine and Gerontology. 8th ed. Elsevier 2017;849-854.
6. Sychev D.A., Otdelenov V.A., Kirilochev O.O. i dr. Polipragmaziya v klinicheskoj praktike: problema i resheniya/ uchebnoe posobie. 2-e izdanie., ispr. i dop. pod obshchej redakciej D.A. Sycheva, Spb.: COP «Professiya», 2018-272s. (In Russ).
7. Leelakanok N., Holcombe A.L, Lund B.C, et al. Association between polypharmacy and death: A systematic review and meta-analysis. J Am Pharm Assoc. 2017;57(6):729-738. doi: https://doi.org/10.1016/j.japh.2017.06.002
8. Gallagher P., Ryan C., Byrne S., et al. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72-83. doi: 10.5414/CPP46072.
9. NICE Medicines and Prescribing Centre (UK). Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. 2015. PMID: 26180890. Bookshelf ID: NBK305021. URL: https://www.nice.org.uk/guidance/ng5
10. Turner G., Clegg A., British Geriatrics Society et al. Best practice guidelines for the management of frailty: a British Geriatrics Society, Age UK and Royal College of General Practitioners report. Age Ageing. 2014;43(6):744–747. doi: https://doi.org/10.1093/ageing/afu138
11. Kendall M. Chairman of the Joint Formulary Committee, British National Formulary. Clin Med (Lond). 2009 Aug;9(4):349-52. doi: https://doi.org/10.7861/clinmedicine.9-4-349
12. Baruth J.M, Gentry M.T, Rummans T.A et al. Multidisciplinary Guideline for Polypharmacy in older people. Hosp Pract (1995). 2020;48(sup1):56-62. doi: https://doi.org/10.1080/21548331.2019.1706995
13. Tkacheva O.N., Nedogoda S.V., Arutyunov G.P. i dr. Metodicheskie rukovodstva: Farmakoterapiya u lic pozhilogo i starcheskogo vozrasta. 2018. ID: MR103. URL: https://rgnkc.ru/images/metod_materials/Farmakoterapiya_2018.pdf. (In Russ).
14. Tkacheva O.N., Kotovskaya YU.V., Runihina N.K., i dr. Klinicheskie rekomendacii: Starcheskaya asteniya. 2020. URL: https://rgnkc.ru/images/metod_materials/KR_SA.pdf. (In Russ).
15. Zabolotskih I.B., Gorobec E.S., Grigor'ev E.V., i dr. Perioperacionnoe vedenie pacientov pozhilogo i starcheskogo vozrasta. Metodicheskie rekomendacii. Vestnik intensivnoj terapii imeni A. I. Saltanova. 2022. №3. 7-26. (In Russ).
16. O’Mahony D., O’Sullivan D., Byrne S., et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–218. doi: https://doi.org/10.1093/ageing/afx178
17. O'Mahony D., Cherubini A., Guiteras A.R., et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-632. doi: https://doi.org/10.1007/s41999-023-00812-y.
18. Thomas R.E, Thomas B.C. A systematic review of studies of the STOPP/START 2015 and American Geriatric Society Beers 2015 criteria in patients ≥ 65 years. Curr Aging Sci. 2019;12(2):121–154. doi: 10.2174/1874609812666190516093742
Review
For citations:
Kotovskaya Yu.V., Tkacheva O.N., Runikhina N.K., Cherniaeva M.S., Malaya I.P., Maslennikova O.M., Egorova L.A., Dotsenko A.A. Enhanced STOPP/START Criteria: A Tool for Managing Polypharmacy in Older Population. Russian Journal of Geriatric Medicine. 2023;16(4):273-288. (In Russ.) https://doi.org/10.37586/2686-8636-4-2023-273-288
Views:
4362
Email this article 